Outset Medical Inc

Outset Medical insider sales spike after earnings, raising questions about valuation, capital structure, and future technology adoption.

Outset Medical’s insider sell‑to‑cover activity shows no loss of confidence; with breakthrough device status and Phase IIb gains, investors should watch upcoming FDA/EMA decisions and the CEO’s J.P. Morgan conference for future valuation clues.